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Abstract
Background: The treatment of venous thromboembolic disease the treatment of choice is systemic
anticoagulation. However, the interruption of the inferior vena cava with filters has been recommended when
anticoagulation fails or there is a contraindication. Due to the rising inferior vena cava filter (IVCF) complications,
physicians are encouraged to retrieve them when there is no longer recommended. In daily practice, it may be a
difficult close follow-up of these patients. In this study, the primary objective was to evaluate the IVCF retrieval rate
of all implanted filters in a Spanish registry. Secondary objectives were to analyze the causes of failed retrieval,
procedure-related complications, and outcomes at a 12-month follow-up.
Results: Three hundred fifty-six vena cava filters were implanted in 355 patients. The types of filter were: Gunther
Tulip (Cook Medical) 160 (44.9%), Optease (Cordis) 77 (21.6%), Celect (Cook Medical) 49 (13, 7%), Aegisy (Lifetech
Scientific) 33 (9.2%), Option ELITE (Argon Medical devices) 16 (4.4%), Denali filter (BD Bard) 11 (3.08%), ALN filter
(ALN) 10 (2.8%).
Removal was achieved in 274/356 (76,9%). eighty-two (23,1%) IVCF were not retrieved due to the following: 41 (11,
5%) patients required ongoing filtration, 24 IVCF (6,7%) patients died before retrieval, and 17 (4,7%) impossibility of
retrieval because of a tilted and embedded filter apex. There were no major complications observed.
Conclusions: The global retrieval rate of IVCF was achieved in 76.9%, and the adjusted retrieval rate was of 94.15%
with no major complications. IVCF tilting was associated with failure of filter removal in less than 5% of cases. This
study demonstrates that the retrieval procedure of IVCF is controlled by the clinician and not by the interventional
radiologist.
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Background
Venous thromboembolic disease (VTD) is a serious
disease that affects 1–2 per 1000 of European citizens
(Monreal et al. 2015). VTE includes acute deep vein
thrombosis (DVT) and pulmonary embolism (PE). The
treatment of choice in VTD is therapeutic systemic
anticoagulation which includes the treatment with:
heparin, low weight heparins, warfarin, acenocoumarol
or the new oral anticoagulants (apixaban, endoxaban,
rivaroxaban, or dabigatran) (Pattullo et al. 2016). When
anticoagulation fails or is contraindicated, inferior vena
cava interruption is recommended, historically it was
performed via surgery, and over the past few decades,
the endovascular procedure is the standard of choice
using various implantable filtration devices with almost
in all devices with a retrievable option (Yunus et al.
2008).
Until the publication of H Decousus, et al. in 1998
(Decousus et al. 1998), even with little clinical evidence,
no one questioned the usefulness of inferior vena cava
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filter (IVCF) for the prophylaxis and treatment of VTD
(Proctor and Greenfield 2008; Athanasoulis et al. 2000;
Stein et al. 2004; Dalen and Stein 2013). It was
Decousus, et al. and the PREPIC study (PREPIC Study
Group 2005) that demonstrated that IVCF represents a
potential benefit with protection against life-threatening
pulmonary embolism in a short-term; however, with a
higher risk of symptomatic DVT in a long-term without
mortality difference at 8 years of follow-up. Therefore,
the use of IVCF decreased in Europe (PREPIC Study
Group 2005; Reddy et al. 2017; Wadhwa et al. 2017).
The arrival of new retrievable IVCF increased the indica-
tions for filter placement, to provide protection against
PE in the short-term while avoiding the long-term DVT
risks by removing the filter in a short period. In the past
decade, it has encountered a rising complication in the
IVCF placement reported in the United States, MAUDE
database (Amendola and Acosta 2016), that resulted in a
Safety Alert issued by the FDA in 2010 (Morales et al.
2013). This safety alert encourages physicians and clini-
cians responsible for the care of patients with IVCF, to
consider removing the filters when there was no longer
an indication of inferior vena cava interruption. (Amen-
dola and Acosta 2016; Food and Drug Administration
2011) However, in daily clinical practice, it may be diffi-
cult to follow patients closely and prompt filter removal.
We present the results of a multicenter prospective
registry involving 15 tertiary Spanish hospitals using a
protocol to facilitate close patient follow-up for prompt
filter removal.
The primary objective of this study was to evaluate all
the inferior vena cava filter (IVCF) retrieval rate of im-
planted IVC filters. Secondary objectives were to analyze
the causes of failed retrieval, procedure-related compli-
cations, and outcomes at a 12-month follow-up.
Material and methods
The SERVEI-REFiVeC (Registro Español de Filtros en
Vena Cava Inferior) Registry is a prospective multicenter
study endorsed by the Spanish Society of Vascular and
Interventional Radiology (SERVEI) and by the Zaragoza
University. This Registry received institutional review
board approval in May 2016 (CP-CI number PI16 /
0142), and the study was registered in Clinical Trial Gov
(NCT02757001). The registry was open from 01 to 04-
16 until 01–04-18. The form was designed by the
research group (GITMI) of the University of Zaragoza.
An electronic patient report form was specifically
designed for this registry and hosted on the Spanish
Society of Vascular and Interventional Radiology (SERVEI),
webpage (Sociedad Española Radiología Intervencionista
(SERVEI), estudios y registros 2020).
This was open to all members of SERVEI society, after
identification and acceptance by the study principal
investigator (PI), and all of the interventional radiologists
(IRs) had at least 5 years in experience for the placement
and retrieval of IVCF. Over 2 years, all patients with an
IVCF implantation were consecutively enrolled by an
electronic registry. The following data were gathered:
demographics, VTE risk factors, filter placement indica-
tions, IVCF type, filter dwell time, number of retrieval
attempts and retrieval outcome (Table 1). The follow-up
was carried out at least 1 year and determined if an ap-
pearance of PE or DVT. In case of clinical suspicion of
PE or DVT, pulmonary CT angiography was performed
for the suspicion of PE or ultrasound- Doppler for DVT.
Complications were classified according to CIRSE stan-
dards (Filippiadis et al. 2017). The study was conducted
following the “Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) Statement:
guidelines for reporting observational studies (von Elm
et al. 2007).
Statistical analysis
We used chi-square or Fisher’s exact tests to compare cat-
egorical data between groups. We used the Shapiro-Wilk
test to assess continuous data for a normal distribution.
We used two-tailed unpaired t-tests to compare para-
metric continuous data between two unpaired groups,
and we used the Mann-Whitney U test for non-









Recovery attemps 1,2,3 …
Death before recovery Yes /NO
Anticoagulant treatment Yes /NO





Set recommended by the
manufacturer
Recovery with other maneuvers Snare, ballooms, cocodrile
clips, grasping
Cause of inability to filter recover Tilt, leg penetration, fibrosis,
thrombosis, death, others
Follow-up 3, 6, 12 months
Recurrence pulmonary
embolism, other causes
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parametric data comparisons. We conducted statistical
analyses using STATA version 13.1 (STATA Corp, Col-
lege Station, Texas). All hypothesis tests were two-sided,
with a significance level of 0.05.
The registry was designed to enroll at least 200 pa-
tients with IVCF and recorded clinical follow-up at least
one year after recovery, evaluating possible episodes of
recurrent PE, DVT or possible death of the patient.
Results
Demographics
From April 2016, until April 2018, three hundred fifty-
six vena cava filters were implanted in 355 patients (1
patient received two filters for having double vena cava).
The mean age was 59.7 ± 13.7 years (range 89–19 years.
One hundred and eighty-two (51.1%) patients were men
and 174 (48.8%) women, 15 Spanish tertiary hospitals
participated in the REFiVeC registry. The average IVCF
implantation in each center was 23.6 ± 25.9 (range 101–
1 IVCF). The types of filter used in the registry were:
Gunther Tulip (Cook Medical) 160 (44.9%), Optease
(Cordis) 77 (21.6%), Celect (Cook Medical) 49 (13, 7%),
Aegisy (Lifetech Scientific) 33 (9.2%), Option ELITE
(Argon Medical devices) 16 (4.4%), Denali (BD Bard) 11
(3.08%), ALN filter (ALN) 10 (2.8%).
Indications
VTD risk factors included immobilization in 197
(55.4%), neoplasm in 55 (15.4%), recent surgery in 46
(12.9%), history of VTE in 35 (9.8%) and contraceptive
use in 24 (6.7%). Of the patients who required a vena
cava filter, 309 had one risk factor for VTD, 43 had two
risk factors, and 4 had more than two risk factors. The
main indications for IVCF were: presence of VTE with
contraindication to anticoagulation in 188 (52.8%), Pre-
vention in high-risk patients with DVT in 120 (33.7%),
(in this case, 54 patients suffered massive PE, 49 suffered
iliofemoral DVT and 17 COPD and DVT), and recurrent
PE despite anticoagulation in 48 (13.4%) (Table 2).
Access and imaging
The access route used for the implantation of the filter
was: the right internal jugular vein in 180 cases (50.5%),
the right femoral vein in 148 (41.5%), the left femoral
vein in 25 (7.02%) and the left internal jugular vein in 2
(0.5%) cases. Cavography was performed in all patients
during filter removal, 260 (73.03%) patients underwent
abdominal computed tomography before IVCF retrieval.
The indication of abdominal CT was to facilitate with-
drawal (knowing the inclination, the presence of throm-
bosis or migration) and was performed on the same day
before the IVCF retrieval. The abdominal CT, 185
(71.1%) patients had normal findings regarding the pos-
ition and tilt of the filter; in 41 (15.7%) patients tilting of
the IVCF was appreciated < 15° with the IVC, in 12
(4.6%) patients IVCF tilt was found > 15°. Penetration of
the legs in the IVC > 3mm was appreciated in 2 (0.76%)
patients, inclusion of the superior hook in the wall of
the IVC or some other element of the filter was observed
in 16 (56.1%) patients, and in 4 (1, 5%) patients had evi-
dence of thrombosis of the IVCF. Three hundred and
one (84.5%) patients were receiving anticoagulation ther-
apy at the time of filter removal, and 55 (154%) patients
were not anticoagulated.
Retrieved IVCF
A total of 274/356 (76.9%) filters were successfully re-
moved. Figure 1 shows the distribution of the retrieved
IVCF. In eighty-two (23,0%) patients, the filters were not
removed, in 41 patients (11,5%) the retrievable filters
were left in as permanent filters (12 patients with ad-
vanced neoplasm, 11 patients refused removal, 13 pa-
tients were older than 70 years and ongoing filtration
was desired due to comorbidities, and five patients were
lost to follow up). In twenty-four (6,7%) patients, the
IVCF was not removed since the patients died during
the follow-up interval at a mean of 18.9 ± 9.6 days (range
2–36 days). Retrieval was not possible in seventeen pa-
tients (4,7%) due to a tilted (> 15 °) and embedded filter
apex. Table 3 shows the IVCF dwell time. The mean
dwell time was 44.8 ± 170.4 days, a median of 31 days
Table 2 The main indication for Inferior Vena Cava Filters
Indications Direct cause n N %
Prevention in high risk patients with DVT - EP massive treated with fibrinolysis o thrombectomy 54 120 33,7
- Iliofemoral DVT 49
- COPD + DVT 17
Contraindication for anticoagulation - Recente bleeding 104 188 52,8
- Recent surgery 42
- Brain tumor /Recent stroke 27
- Severe trauma 15
Recurrence of pulmonary embolism while receiving anticoagulation 48 13,4
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(ranging 1–2920 days). Table 4 shows the number and
the percentage of each type of filters that were not re-
covered, as a result of the patients had died, could not
be retrieved or because they were left as permanent
filters.
Difficulties and complications
Removal difficulties occur in 26 patients (7.3%) (mainly
related to tilting > 15 ° and inclusion of the upper hook
or some structure in the wall of the IVC.
Special endovascular maneuvers were performed to re-
trieve filters with an average of 2.8 maneuvers, with a
range of 1–4 additional maneuvers (femoral-jugular
double access, Snare-Loop Technique, the Hangman
Technique) and repeated attempts at recovery in 9/26
patients, IVCF was recovered with an average of 2.1 at-
tempts (range 1–3). Despite several attempts (average
2.5 and 1–3 range) in 17/26 patients, IVCF could not be
recovered and was left as permanent filters (Fig. 2)
(Table 5). Of the IVCF defined as retrievable filters
(without patients who died and those who for various
reasons were left as permanent filters), the global re-
moval success was 76.96%. When comparing the dwell
time of the filters extracted successfully and in which it
failed, the average period was 35.2 ± 15 days with a me-
dian 32 days for the extracted ones versus 65 ± 56 days
on average with a median of 48 days in the that failed
(p = 0.0011). IVCF thrombosis was observed in four
patients (1.2%). After fibrinolysis in two patients and
thromboaspiration in 2, the filter could be removed
without any complications. Complications were found in
12 patients (3.3%): 6 neck hematomas and 5 groin
hematoma, (type I complication) (Filippiadis et al. 2017).
Accidental carotid punctured in 1 patient, which
Fig. 1 Diagram showing the distribution of inferior vena cava filters. Filters retrieved successfully and unable to retrieve filters with their causes
Table 3 Days until the filter was retrieved in each type of filter, either satisfactorily or failed as well as the range (maximum and
minimum days for each type of filter)
Filter (356) N % Mean days until retrieval Range days p
Successful Failed Min Max
Gunther Tulip (Cook) 160 44,9 146/64,6 2/87,5 1 2920 < 0.01
Optease (Cordis) 77 21,6 44/29,1 11/48,09 12 98 < 0.01
Celect (Cook) 49 13,7 42/ 41,1 2/151 19 270 < 0.01
Aegisy (Lifetech 33 9,2 20/14,9 1/13 11 27 0.05
Option ELITE (Argon) 16 4,4 11/32,3 1/28 26 41 0.01
Denali (Bard) 11 3,08 8/31 0/0 26 35 0.04
ALN Filter (ALN) 10 2,8 8/32,3 0/0 26 366 0.04
TOTAL 356 1 2920
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required compression and admission of 24 h (type II
complication) (Filippiadis et al. 2017). In 276 (77.5%)
patients, fluoroscopy time and Air Kerma were studied
(Table 6).
Follow-up
In 264 (74.1%) patients, follow-up time was 11.3 ± 3.2
months after IVCF recovery. All patients were treated
with oral anticoagulation or low molecular weight be-
tween 6 and 8months. There were 2 cases of recurrence
of PE after IVCF retrieval. Both were documented with
pulmonary CT angiography, echocardiography, and bio-
logical markers. One of them, occurred when the patient
was not anticoagulated, and was classified as a low-
intermediate risk for PE and was treated with new oral
anticoagulant treatment. The other, a young patient,
Table 4 Distribution by type of filter (Successful withdrawal or failure, as well as filters that could not be removed because the
patient died during their hospital stay or for various reasons, were left as permanent filters)
Filter N % Successful Failed Dead* Permanent p
Gunther Tulip (Cook) 160 44,9 146 /91,2% 2/1,2% 9/5,6% 2/1,2 < 0.01
Optease (Cordis) 77 21,6 42/54,5% 11/14,2% 6/7,7% 17/22,0% < 0.01
Celect (Cook) 49 13,7 42/85,7% 2/4,0% 2/4,0% 2/4,0% < 0.01
Aegisy (Lifetech 33 9,2 20/60,6% 1/3,0% 3/9,0% 12/36,3% < 0.1
Option ELITE (Argon) 16 4,4 11/68,7% 1/6,25% 1/6,2% 4/25% 0.05
Denali (Bard) 11 3,08 7/63,6% 0/0 1/9,0% 3/27,7% 0.04
ALN Filter (ALN) 10 2,8 6/60% 0/0 2/20 1/10% 0.04
356 274 17 24 41
* Patients died before inferior vena cava filter was scheduled for retrieval
Fig. 2 Example of IVCF retrieval with difficulty. A 61-year-old female patient diagnosed with multiple myeloma. Six years ago she had DVT in her
left lower limb. She was treated with unfractionated heparin and had an upper-GI bleed, and anticoagulants became contraindicated. An Optease
filter was implanted infrarenal. a. abdominal x-ray showed the Optease filter in a proper position. b. Abdominal CT with sagittal MPR showed the
filter slightly tilted on the vertical axis. c. Femoral access with a 16 Fr sheath and a 25 mm snare (Amplatz GooseNet snare). After several attempts,
it was impossible to recover it. d. Jugular access was made with a 12 F sheath and a guide was passed through the upper vertex of the filter and
with several movements from both accesses, the IVCF was introduced into the sheath and the filter could be recovered. e. Cavography after filter
retrieval (shows endothelial alteration). f. The filter recovered with endothelial remains
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diagnosed with hematologic disease and hereditary
thrombophilia (homologous Leiden Factor V) was
decided on the new placement of definitive filter and
anticoagulation treatment for life.
Discussion
The SERVEI-REFiVeC registry is a study of 356 retriev-
able ICVFs in 355 patients, which gathers the activity of
fifteen major Spanish hospitals. This study has limita-
tions since in Spain, there is no consensus, protocol or
guidelines accepted by the different societies regarding
VTD regarding placement and retrieval of IVCF. Inter-
ventional Radiologists are aware of the recommenda-
tions of the FDA and other administration to remove all
filters as soon as possible, once they are no longer
needed. The total recovery rate of FVCI in this study
was 76.9%, it might seem low if we compare it with the
data from the CIRSE Registry (De Gregorio et al. 2006)
in which the recovery rate is 92%. Other non-
multicenter studies (De Gregorio MA et al.) (Sarosiek
et al. 2013) reach 96% success in recovery. However, the
British Society of Interventional Radiology (BSIR) regis-
try (Lee et al. 2015) presents similar or even lower data
(426/514) 66,9%, other authors such as Sarosiek et al. in
2013 (de Gregorio et al. 2018) in a series of 679 retriev-
able filters only 58 (8%) were removed.
The differences can be very important because the
study designs are different. In the present SERVEI-
REFiVeC study, after withdrawing patients which had
died 24(6%), and 41 (11.5%) patients with the initial
intention to retrieve the filter, but finally for different
reasons or because there is no clear protocol in their
hospital, the petitionary clinician decided not to remove
the filter. The adjusted retrieval rate of Vena Cava Filters
in SERVEI-REFiVeC reaches 94.15% (291/356). Only in
17 patients (4.7%) was attempted for retrieval but was
not possible for different reasons.
Several studies have shown that the retrievability of
different types and models of filters is similar and there
are no significant differences (Sarosiek et al. 2013;
Uberoi et al. 2013a; Lyon et al. 2009; Rimon et al. 2009;
Pellerin et al. 2008; Uberoi et al. 2013b; Deso et al. 2016;
Kuo et al. 2012). The importance of the retrievable filters
is recoverability property, because it is a thrombogenic
device, that according to various studies provides it
limited clinical benefit and can cause complications
(Decousus et al. 1998; PREPIC Study Group 2005;
Amendola and Acosta 2016).
It seems that the main difficulty for the recovery of
these retrievable filters is the tilting and the embedded
apex which may result in fibrosis or endothelialization of
the device components into the wall (Uberoi et al.
2013a; Lyon et al. 2009). These factors could be pre-
vented by the operator by improving the implantation
technique, and the dwell time of the device. It is import-
ant an advanced technique in the implantation of the fil-
ter, avoiding tilting > 15°. On the other hand, the FDA
recommends the removal of the filters as soon as pos-
sible when vena cava interruption is no longer needed.
This logical recommendation, together with the
Table 5 Main causes of IVCF recovery failure and number retrieval attempts
Filter N Failed Reasons for failed Recovery Attemps
Gunther Tulip (Cook) 160 2/1,2% -Tilt> 15°, Hook included in IVC wall 2
- Hook and legs included in IVC wall 3
Optease (Cordis) 77 11/14,2% - Legs and structures included in IVC wall 2 (5 pats)
- Legs and structures included in IVC wall 1 (6 pats.)
Celect (Cook) 49 2/4,0% -Tilt> 15°, Hook included in IVC wall 2
- Tilt> 15°, Hook included in IVC wall 1
Aegisy (Lifetech) 33 1/3,0% - Legs and structures included in IVC wall 1
Option ELITE (Argon) 16 1/6,25% -Tilt> 15°, Hook included in IVC wall 2
Denali (Bard) 11 0/0 –
ALN Filter (ALN) 10 0/0 –
356 17
(Pats: Patients)
Table 6 Fluoroscopy time and Air Kerma data for retrieval
procedure (successful and failed filter retrieval)
Recovery Fluoroscopy time Minutes Air Kerma mGy p
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operator’s responsibility, is to suggest the referring phys-
ician and the patient retrieve the filter as soon as pos-
sible and avoid retrievable procedures with long dwelling
time which may present more difficulty and possible
complications.
The advanced skills of the operator must not be only
evident in the implantation of the filter, but also be able to
manage different devices and additional retrieval maneu-
vers (Iliescu and Haskal 2012; Desai et al. 2017). In this
study, additional maneuvers were used in 33 (9.2%) pa-
tients. Despite these additional maneuvers, half of the
cases (17 patients / 4.7%) the filters could not be removed.
Prolonged filter dwell time has been associated with a
more difficult recovery of the filter, and an increase in
complications secondary to the retrieval procedure. The
complications include: device fracture, migration, organ
penetration by device components, and an elevated risk
of thrombosis / DVT (Andreoli et al. 2014). MAUDE
(Manufacturer and User Facility Device Experience)
(White et al. 2013) has published a high rate of compli-
cations in the handling of retrievable filters, which has
led the FDA in this same year to do a serious communi-
cation insisting to withdraw the FVCI as soon as pos-
sible. However, the main filter recovery records do not
reveal significant and serious complication rates
(Sarosiek et al. 2013; Uberoi et al. 2013a; Deso et al.
2016). In this study, complications related to the access
route in the jugular vein were found, the most important
an accidental puncture of the carotid artery. There was
also no relationship between the difficulties of IVCF
recovery and the filter dwell time.
Recent studies have questioned the efficacy of IVCF
(Dalen and Stein 2013). Some studies have been pointed
out the controversial role of IVCF in the treatment of
the VTD. The existence of great variability in the use of
filters between hospitals with similar indications of 0%
to 38% is known (Prasad et al. 2013). Some authors
doubt the effectiveness of IVCF in the protection against
PE since in a series of 504 patients with PE and IVCF
7.8% presented recurrence of PE despite the filter (de
Gregorio et al. 2018; Kearon et al. 2012). The guidelines
of the American College of Chest Physicians (ACCP)
and the European Society of Cardiology (ESC) in their
recommendations reserve the use of IVCF for the failure
and/or contraindication of anticoagulation (Konstantinides
et al. 2019; Kearon et al. 2016).
The PREPIC 1 study (Decousus et al. 1998) reinforced
by the PREPIC 2 study, (PREPIC Study Group 2005)
based on IVCF, initially it decreases PE but increases the
rate of DVT and does not influence the mortality of
VTD. Current guidelines do not recommend IVCF in
anticoagulated patients with VTD (Recommendation 1B)
(Dalen 2012).
Even though retrievable filters have largely replaced
permanent filters, there is still not enough clinical evi-
dence to increase IVCF indications and modify current
guidelines (Uberoi et al. 2013a). The use of a retrievable
IVCF with a prompt removal is theoretically consistent
with the conclusions of both PREPIC studies (Decousus
et al. 1998; PREPIC Study Group 2005). Recoverable fil-
ters could potentially be effective in the prevention of
life-threatening PE in the short-term. IVCF should be re-
moved as soon as possible when their presence is no
longer needed, and avoid filter-related complications in-
cluding long-term post-thrombotic syndrome. In this
study, the 2016 ACCP filter guidelines (Kearon et al.
2016) were closely followed and the indications for filter
placement were absolute in 66.2%, in contrast to the
CIRSE Registry where absolute indications were only
40% (Uberoi et al. 2013a).
Retrievable IVCF has demonstrated efficacy in patients
with unstable PE (Dalen and Stein 2016; Stein et al.
2012). In patients with unstable PE, hospital mortality
was 18% in patients with fibrinolytic therapy alone, while
hospital mortality was reduced to 7.6% when IVCF was
used (p < 0001) (Stein et al. 2012). However, despite the
big difference in the number of filters implanted per
capita in the US versus Europe, the overall death rate
from PE in both populations remains similar (Uberoi
et al. 2013a).
There are important limitations of this study, even
though the study was supported by SERVEI, only 15
hospitals participated, and Spain has a total of 118 hos-
pitals with IR (De Gregorio and Urbano 2017). The
number of participants was small and does not resemble
the absolute truth of the implantation of IVCF in Spain.
In our opinion, there are too many IVCF left as perman-
ent filters (41/11.5%). The involvement of the interven-
tional radiologists in the decision to remove or leave the
IVCF as permanent is unknown. However, the study
objective was not to show the retrieved filters but
implanted filters and their possibility of recovery, which
shows us a real situation within a small sample. A guide
or clinical consensus for the management of IVCF
should be promoted from the scientific societies regard-
ing VTD. Finally, it would be necessary to perform a
multicenter, and multinational registry in Europe to
determine the exact use of IVCF and their retrieval rate.
Conclusion
In conclusion, IVCF retrieval was achieved > 75% in a
cohort with no major procedural complications. IVCF
tilting and embedded apex was associated with failure of
filter removal in less than 5% of cases. This paper does
not demonstrate a good correlation between the diffi-
culty of the IVCF recovery and the dwell time. The glo-
bal retrieval rate was of 76.9%, however the adjusted
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retrieval rate was of 94.15% comparable with recent
studies. This study demonstrates that the retrieval pro-
cedure of IVCF is controlled by the clinician and not by
the interventional radiologist.
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